Annual Report 2011
Get more background on Actelion’s worldwide reach, new discovery projects and continuous commitment to PAH.
Actelion is a biopharmaceutical company with four products on the market. We are proud to have one of the richest product pipelines among pharmaceutical companies of comparable size.
Our team of more than 2,500 committed professionals around the world is passionate about transforming innovation into new medicines.
2011 was a commercially successful year for Actelion despite the challenging macro-economic environment.
Actelion has a broad and well-balanced pipeline with more than 15 compounds in development in various therapeutic indications.
Actelion's Articles of Associoation, its By-Laws and its Policy on Ethical Conduct, all provide the basis for its principles of Corporate Governance.
Actelion’s Corporate Responsibility reflects the company’s mission to provide innovative medicines for unmet medical needs in a responsible, respectful and ethical manner.
Actelion achieved strong results with product sales of more than CHF 1.7 billon. However, these results were adversely affected by the ongoing economic crisis.